Abstract
Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Anti-Infective Agents
Title:Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis
Volume: 10 Issue: 2
Author(s): Azam J. Samdani, Samreen, M. Iqbal Choudhary and Atta-ur-Rahman
Affiliation:
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Abstract: Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Export Options
About this article
Cite this article as:
J. Samdani Azam, Samreen , Iqbal Choudhary M. and Atta-ur-Rahman , Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020111
DOI https://dx.doi.org/10.2174/2211362611208020111 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Probiotic Preparations on Inflammatory Cytokines in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
Current Pharmaceutical Biotechnology Editorial from Editor-in-Chief
Current Rheumatology Reviews Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones
Current Pharmaceutical Biotechnology Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications
Current Nutrition & Food Science Discovery of Highly Selective Inhibitors of p38α
Current Topics in Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Editorial [Hot Topic: Murine Atherosclerosis (Part II) (Guest Editor: Godfrey S. Getz)]
Current Drug Targets Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Glioblastoma Therapy – Part I (Guest Editor: Hui-Wen Lo)]
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis and AngiomiRs in Non-Hodgkin´s Lymphomas
Current Angiogenesis (Discontinued) Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Cannabis for Refractory Psoriasis—High Hopes for a Novel Treatment and a Literature Review
Current Clinical Pharmacology Development of New Immunotherapies for Japanese Cedar Pollinosis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Renal Alterations Promoted By The Lectins From Canavalia Ensiformis (Cona) And Dioclea Guianensis (Dguil) Seeds
Protein & Peptide Letters Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease
Current Clinical Pharmacology Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets